-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tagraxofusp in Systemic Mastocytosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tagraxofusp in Systemic Mastocytosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tagraxofusp in Systemic Mastocytosis Drug Details: Tagraxofusp (Elzonris) acts as an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SCT-1000 in Vaginal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SCT-1000 in Vaginal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SCT-1000 in Vaginal Cancer Drug Details: SCT-1000 is under development for the...
-
Product Insights
Myoclonic Seizure – Drugs In Development, 2023
Global Markets Direct’s, ‘Myoclonic Seizure - Drugs In Development, 2023’, provides an overview of the Myoclonic Seizure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myoclonic Seizure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Generalized Seizures – Drugs In Development, 2023
Global Markets Direct’s, ‘Generalized Seizures - Drugs In Development, 2023’, provides an overview of the Generalized Seizures pipeline landscape. The report provides comprehensive information on the therapeutics under development for Generalized Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Vascular Dementias – Drugs In Development, 2023
Global Markets Direct’s, ‘Vascular Dementias - Drugs In Development, 2023’, provides an overview of the Vascular Dementias pipeline landscape. The report provides comprehensive information on the therapeutics under development for Vascular Dementias, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Seizures – Drugs In Development, 2023
Global Markets Direct’s, ‘Seizures - Drugs In Development, 2023’, provides an overview of the Seizures pipeline landscape. The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Fragile X Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Fragile X Syndrome - Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hearing Disorders – Drugs In Development, 2023
Global Markets Direct’s, ‘Hearing Disorders - Drugs In Development, 2023’, provides an overview of the Hearing Disorders pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hearing Disorders, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Schizophrenia – Drugs In Development, 2023
Global Markets Direct’s, ‘Schizophrenia - Drugs In Development, 2023’, provides an overview of the Schizophrenia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...